TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6110384
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg or 30 mg orally 1 hour before surgery
Study: 31577875
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy for 28 weeks (immediate group)
Study: 31577875
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy for 28 weeks (deferred group)
Study: 31577875
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (immediate group)
Study: 31577875
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (deferred group)
Study: 29632870
Drug: Dopamine D2/D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/D3 receptor antagonist sulpiride
Study: 26657824
Drug: Loulla (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loulla (liquid formulation of 6-mercaptopurine)
Study: 26657824
Drug: Registered tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registered tablets (control)
Study: 12378877
Drug: Psychopharmacotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacotherapy combined with cognitive behavioural therapy
Study: 8793607
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac
Study: 1638335
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg disulfiram
Study: 10594487
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml grapefruit juice twice daily
Study: 10594487
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin 4 times daily
Study: 26874645
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg/d, titrated to 30 or 60 mg/d)
Study: 17506866
Drug: Cardio-selective beta(1)-adrenergic
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardio-selective beta(1)-adrenergic blockade (0.15 mg kg(‐1) metoprolol)
Study: 11927516
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of concentrated ambient fine particles (CAP) plus ozone (120 ppb) for 2 hours
Study: 11927516
Drug: Filtered air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered air inhalation
Study: 8137988
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment to induce immunosuppression
Study: 22032343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (650 ml tea)
Study: 16911649
Drug: Topical racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical racemic adrenaline (RA) 1:500
Study: 9166464
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant systemic therapy
Study: 10681072
Drug: Losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50-100 mg)
Study: 31012566
Drug: Epicutaneous heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicutaneous heat patch applied for 2 hours per day for 12 weeks
Study: 31012566
Drug: Epicutaneous heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicutaneous heat patch
Study: 21916638
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine FMP2.1/AS02(A)
Study: 19806414
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment Control (C)
Study: 11411059
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 x 850 mg)
Study: 8677878
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at dosages of 10 to 320 ng/kg/min
Study: 8677878
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at dosages of 40 ng/kg/min
Study: 8677878
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at dosages > 80 ng/kg/min
Study: 31036542
Drug: NP-S +
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP-S + GM-CSF (1,000 μg NP-S + 250 μg GM-CSF monthly for 6 months, then every 6 months through 36 months)
Study: 31036542
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + GM-CSF (monthly for 6 months, then every 6 months through 36 months)
Study: 2510657
Drug: Cadralazine 10
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine 10 mg o.d.
Study: 1159434
Drug: Anticoagulants for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants for an average period of 18 months
Study: 28835271
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU vitamin D3 daily
Study: 25877802
Drug: Zinc Glycinate
Normalized name: Zinc Glycinate
DrugBank: Zinc glycinate citrate (DB15556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc Glycinate (60 mg Zn/day)
Study: 25877802
Drug: Zinc Gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc Gluconate (60 mg Zn/day)
Study: 24157649
Drug: EHR-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR-based medication management tools alone
Study: 24157649
Drug: EHR tools
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR tools plus nurse-led medication therapy management
Study: 21748203
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 μg intravaginally every 4 hours (maximum 6 doses)
Study: 6785336
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy
Study: 8368410
Drug: Diclofenac, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac, 75 mg twice daily for 3 to 5 days before and for 7 days after surgery
Study: 27184170
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg
Study: 27595147
Drug: pexacerfont (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: pexacerfont (300 mg/day for 7 days, then 100 mg/day for 21 days)
Study: 18788033
Drug: Unipolar RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unipolar RF treatment
Study: 18727024
Drug: Bipolar RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar RF treatment
Study: 10030326
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria)
Study: 10030326
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (followed Danish guidelines)
Study: 7575052
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment alone (prednisolone)
Study: 2341751
Drug: High-dose human
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose human leukocyte interferon-alpha (IFN-alpha)
Study: 7396099
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (i.v. administered)
Study: 25918727
Drug: sulodexide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide 100 mg/day for 14 weeks
Study: 19542797
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (MCT) patch
Study: 17854237
Drug: Hydralazine capsule
Normalized name: hydralazine Oral Capsule
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydralazine capsule plus ISDN tablet (V‐HeFT I formulation)
Study: 17854237
Drug: Hydralazine tablet
Normalized name: hydralazine Oral Tablet
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydralazine tablet plus ISDN tablet (V‐HeFT II formulation)
Study: 17854237
Drug: FDC ISDN/HYD
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC ISDN/HYD (A‐HeFT formulation)
Study: 11543695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate, sulfasalazine, and hydroxychloroquine
Study: 11543695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate and cyclosporin
Study: 11543695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-TNF therapy with methotrexate
Study: 11543695
Drug: Corticosteroids in
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids in addition to the combination therapies
Study: 11543695
Drug: Other combinations
Normalized name: Iron in other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other combinations involving parenteral gold, penicillamine, and azathioprine
Study: 9600553
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin A (BtA)
Study: 7973470
Drug: Psychoeducational family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational family management with standard dose or targeted medication
Study: 2681764
Drug: Continuous allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous allopurinol therapy
Study: 2681764
Drug: Intermittent allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent allopurinol therapy (2 months every year)
Study: 18326616
Drug: Isoflavone-enriched foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-enriched foods providing a mean daily intake of 110 mg isoflavone aglycones
Study: 14740274
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.1 IU/kg)
Study: 14740274
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (0.1 IU/kg)
Study: 14740274
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine and regular human insulin
Study: 1299490
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (365 mg per day)
Study: 31107956
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment
Study: 30107419
Drug: Combination nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine patch and lozenge
Study: 30107419
Drug: Patch monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch monotherapy
Study: 29935535
Drug: Intravenous propacetamol
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propacetamol followed by oral placebo
Study: 29935535
Drug: Oral dexibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexibuprofen after intravenous 0.9% sodium chloride solution
Study: 25172878
Drug: Low-dose PAZ320
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PAZ320 (8 g)
Study: 25172878
Drug: High-dose PAZ320
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PAZ320 (16 g)
Study: 20455890
Drug: Individualized GH
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized GH treatment (17-100 microg/kg/day)
Study: 20455890
Drug: Standard GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GH dose treatment (43 microg/kg/day)
Study: 15994746
Drug: Individualized GH
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized GH treatment
Study: 12854177
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn extract, 15 g 3 times a day for 6 months
Study: 12854177
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex one tablet, 3 times a day for 6 months
Study: 10702196
Drug: Tegaserod, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod, 2 mg twice daily for 1 week
Study: 8225212
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/kg, intravenously)
Study: 29478970
Drug: Sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin plus GHR antagonist
Study: 20556256
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement (ridge preservation with grafting)
Study: 18854562
Drug: Amrubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin (40 mg/m² on days 1-3)
Study: 18854562
Drug: Topotecan (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.0 mg/m² on days 1-5)
Study: 10569660
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/day) + placebo (E+P)
Study: 10569660
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) + placebo (L+P)
Study: 10569660
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Losartan (E+L)
Study: 8702449
Drug: Treatment counseling
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment counseling telephone intervention
Study: 1649715
Drug: Gliclazide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80 mg) administered 90 min before glucose clamp
Study: 30318893
Drug: Propofol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (average up to 115 mg in boluses of 20 mg) plus placebo (saline solution)
Study: 30318893
Drug: Midazolam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (3 mg) plus propofol (average up to 83 mg in boluses of 20 mg)
Study: 27095338
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing and Cognitive Behavioral Therapy (MICBT) plus standard care
Study: 11893228
Drug: Old antiepileptic
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old antiepileptic drugs (AEDs)
Study: 7610938
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg
Study: 19033149
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT)
Study: 21269858
Drug: Single 60‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 60‐mg/kg dose of azithromycin extended‐release (ER)
Study: 21269858
Drug: 10‐day regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day
Study: 19384185
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) used as an early drug in a calcineurin inhibitor-free protocol in the first 3 months after transplantation
Study: 16924010
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIg) treatment
Study: 15675752
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy using benzylpenicillin in control group
Study: 15675752
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy using benzylpenicillin in prophylaxis group
Study: 16403928
Drug: Beta-blocker alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker alone
Study: 16818810
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus beta-blocker
Study: 16403928
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus beta-blocker vs beta-blocker alone
Study: 16403928
Drug: Sotalol vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol vs beta-blocker alone
Study: 16403928
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus beta-blocker vs sotalol
Study: 10319306
Drug: Metrogel Vaginal
Normalized name: MetroGel Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrogel Vaginal (one applicator twice daily for five days)
Study: 10319306
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg twice daily for seven days by mouth)
Study: 6784566
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (2%, 15 mg) administered every 6 hours for 48 hours
Study: 6784566
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment administered every 6 hours for 48 hours
Study: 29064909
Drug: Pexacerfont (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexacerfont (300, 200, and 100 mg/day in the first, second, and third week, respectively)
Study: 16336673
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder mannitol (M)
Study: 9633846
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2, 24‐hour infusion) plus cisplatin (75 mg/m2)
Study: 9633846
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2, 3‐hour infusion) plus carboplatin dosed to an area under curve of 7.5
Study: 9633846
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents (topotecan, gemcitabine, oral etoposide, encapsulated doxorubicin)
Study: 29938621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ω‐3 fatty acids (2500 mg) plus nano‐curcumin (80 mg)
Study: 29938621
Drug: ω‐3 (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 (2500 mg)
Study: 29938621
Drug: Nano-curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (80 mg)
Study: 29938621
Drug: Control (ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ω‐3 and nano‐curcumin placebo included oral paraffin oil)
Study: 22733286
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B - individual adjustments of treatment sphere and treatment cylinder
Study: 12095666
Drug: Methadone (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (standard prison treatment)
Study: 8123862
Drug: Bu/Cy2 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu/Cy2 regimen with monoclonal antibody-purged bone marrow
Study: 8123862
Drug: Cy/fTBI regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cy/fTBI regimen with monoclonal antibody-purged bone marrow
Study: 2775611
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (50 mg) dissolved in homogenized meal (C)
Study: 2775611
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (50 mg) dissolved in phosphate buffer pH 7.5 (B)
Study: 2775611
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (50 mg) dissolved in water (A)
Study: 27639439
Drug: Hyaluronan (HA)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (HA) injections
Study: 25889091
Drug: Glucose-lowering oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-lowering oral agents
Study: 23462724
Drug: AGI004 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI004 4 mg then 8 mg per 24 h transdermal patch
Study: 23462724
Drug: AGI004 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI004 8 mg per 24 h transdermal patch
Study: 23462724
Drug: AGI004 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI004 4 mg per 24 h transdermal patch
Study: 21297494
Drug: POM3 (omega-3-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: POM3 (omega-3-acid ethyl esters, 4 g/day)
Study: 18304964
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT) with cyclophosphamide (1500 mg/m2), thiotepa (150 mg/m2), and mitoxantrone (10 mg/m2) for four consecutive days followed by stem cell transplantation
Study: 18304964
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (SD-CT) with three cycles of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Study: 15705206
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (budesonide 400 mug)
Study: 12074350
Drug: Cilazapril (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.0 mg/day)
Study: 12074350
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg/day)
Study: 7486038
Drug: edrophonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium (1 mg/kg)